Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a report published on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The stock has a market cap of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.